Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210713 · ClinicalTrials.gov registry record · Phase 1
Neuroimmune Dysfunction in Alcohol Use Disorder
A Phase 1 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 1
- Development phase
- 142
- Enrollment target
NCT04210713 is a Phase 1 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 142 participants.
The verdict
NCT04210713, a Phase 1 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 142 participants
- Enrollment target
Study Summary
The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.
Interventions
- DRUG Minocycline
- DRUG Sugar pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2023-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210713
The ClinicalTrials.gov registry entry for NCT04210713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Minocycline is the first listed.
NCT04210713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210713 about?
NCT04210713 is a clinical study titled "Neuroimmune Dysfunction in Alcohol Use Disorder". The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol u...
What is the current status of trial NCT04210713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 142 participants. The study started on 2020-02-03. Estimated completion is 2023-09-20.
What interventions are being tested in trial NCT04210713?
The interventions under investigation include: Minocycline (DRUG), Sugar pill (DRUG).
Who is sponsoring clinical trial NCT04210713?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.